

PATENT

Case Docket No. DECLE26.001C1

Date: April 5, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Rousseau, et al.
Appl. No. : 10/802,089
Filed : March 16, 2004
For : PHARMACEUTICAL
COMPOSITION FOR
TREATING OR PREVENTING
DIABETES OR CANCER, OR
THE WAARDENBURG
SYNDROME
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 5, 2004

(Date)

Che S. Chereskin

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 citing eleven (11) references (not included).
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Che S. Chereskin


Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Rousseau, et al.
App. No. : 10/802,089
Filed : March 16, 2004
For : PHARMACEUTICAL COMPOSITION
FOR TREATING OR PREVENTING
DIABETES OR CANCER, OR THE
WAARDENBURG SYNDROME
Examiner : Unknown
Group Art Unit : Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 11 references that are of record in U.S. patent application No. 09/763,535, filed July 2, 2001, which is the parent of this continuation application, and is relied upon for an earlier filing date under 35 U.S.C. § 120. Copies of the references are not submitted pursuant to 37 C.F.R. § 1.98(d).

This Information Disclosure Statement is being filed within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 5, 2004

By: Che S. Chereskin
Che Swyden Chereskin, Ph.D.
Registration No. 41,466
Agent of Record
Customer No. 20,995
(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
DECL26.001C1APPLICATION NO.
10/802,089INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Rousseau, et al.FILING DATE
March 16, 2004GROUP
Unknown

(USE SEVERAL SHEETS IF NECESSARY)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/11254	03/19/98	WIPO				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Landry, et al. "HNF-6 is Expressed in Endoderm Derivatives and Nervous System of the Mouse Embryo and Participates to the Cross-Regulatory Network of Liver-Enriched Transcription Factors," <i>Developmental Biology</i> , Vol. 192, pp. 247-257, December 15, 1997
	Lannoy, et al. "Isoforms of Hepatocyte Nuclear Factor-6 Differ in DNA-Binding Properties, Contain a Bifunctional Homeodomain, and Define the New ONECUT Class of Homeodomain Proteins," <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 22, pp. 13552-13562, May 29, 1998.
	Rausa, et al., "The Cut-Homeodomain Transcriptional Activator HNF-6 is Coexpressed with Its Target Gene HNF 3 β in the Developing Murine Liver and Pancreas," <i>Developmental Biology</i> , Vol. 192, pp. 228-246, December 15, 1997.
	Spek, et al. "Type I Protein C Deficiency Caused by Disruption of a Hepatocyte Nuclear Factor (HNF)-6/HNF-1 Binding Site in the Human Protein C Gene Promoter," <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 17, pp. 10168-10173, April 24, 1998.
	Vaisse, et al., "Pancreatic Islet Expression Studies and Polymorphic DNA Markers in the Genes Encoding Hepatocyte Nuclear Factor-3 α , -3 β , -3 γ , -4 γ and -6," <i>Diabetes</i> , Vol. 46, No. 8, pp. 1364-1367, August, 1997.
	Jacquemin, et al. "OC-2, a Novel Mammalian member of the ONECUT Class of Homeodomain Transcription Factors Whose Function in Liver Partially Overlaps with that of Hepatocyte Nuclear Factor-6," <i>Journal of Biological Chemistry</i> , Vol. 274, No. 5, pp. 2665-2671, January 29, 1999.
	Lemaigre, et al., "Hepatocyte Nuclear Factor 6, a Transcription Factor that Contains a Novel Type of Homeodomain and a Single Cut Domain," <i>Proceedings of the National Academy of Sciences</i> , Vol. 93, pp. 9460-9464, 1996.
	Sigmund. "Viewpoint: Are Studies in Genetically Altered Mice Out of Control?" <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> , Vol. 20, pp. 1425-1429, 2000.
	Vanhorenbeeck, et al. "OC-3, a Novel Mammalian Member of the ONECUT Class of Transcription Factors," <i>Biochemical and Biophysical Research Communications</i> , Vol. 292, pp. 848-854, 2002.
	Jacquemin, et al. "The Transcription Factor ONECUT-2 Controls the Microphthalmia-Associated Transcription Factor Gene," <i>Biochemical and Biophysical Research Communications</i> , Vol. 285, pp. 1200-1205, 2001.

H:\DOCS\CSC\CSC-6846.DOC
033104

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	